Nuvectis Pharma, Inc.

NASDAQ: NVCT · Healthcare · Biotechnology

PublicHQ Fort Lee, NJ · BergenCIK 0001875558Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 44DQ —GM —SS 40

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, filing timeliness · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$26.4M

Employees

as of 2026-08-11

Market cap

$500.9M

as of 2026-08-11

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$26.4M-$26.4M2025

Operating income-$27.6M-$27.6M2025

Total assets$31.7M$31.7M2025

Liabilities$13.3M$13.3M2025

Equity$18.4M$18.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Nuvectis Pharma, Inc.’s financial profile?

Nuvectis Pharma, Inc. earned -$26.4M in FY2025 net income.

Peers · Healthcare

Odyssey Therapeutics, Inc.——Zura Bio Limited——MapLight Therapeutics, Inc.——Eikon Therapeutics, Inc. Common Stock——Kyverna Therapeutics, Inc.——Cabaletta Bio, Inc.——

Neighbors

Bergen →

Becton, Dickinson and Company$21.8B83B+Balchem Corp$1.0B84B+Versant Media Group, Inc. Class A$6.7B57C Columbia Financial, Inc.——ADMA Biologics, Inc.$510.2M85A Innodata Inc.$251.7M81B+

Key facts

CEORon Bentsur

SectorHealthcare

IndustryBiotechnology

HeadquartersFort Lee, NJ

ExchangeNASDAQ: NVCT

Employees13

IPO date2022-02-04

Latest filings

8-K2026-08-21 10-Q2026-08-04 8-K2026-08-04 8-K2026-06-30 8-K2026-06-29 8-K2026-06-23 8-K2026-06-12 8-K2026-05-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.